Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

Capital Raise Sizing Calculator: How Much to Raise and What It Costs in Dilution

To size the raise, multiply monthly burn by your target runway and add your one-time uses of funds. Add a contingency buffer to that total, then gross it up for transaction costs. Dilution is the gross raise divided by the post-money value.

Here is an example. A company burns $150,000 a month, needs 18 months of runway and has $1 million of build-out to fund. Apply a 20% buffer, 4% transaction costs and a $12 million pre-money valuation. The company needs a gross raise of $4,625,000, and new investors take 27.82%. That is our arithmetic, and each step is shown below.

Data current as of November 20, 2026. Each figure names its source and as-of date: PESP 2025 deal review, Sikich Q3 2026 update (reporting PitchBook data), BuckheadFMV control transactions January 2023 to October 2026, Axia Growth closed sales as of October 28, 2026, Damodaran (NYU Stern) January 2026, Kaufman Hall Q3 2026 report dated October 13, 2026.

Estimate only. Educational, not investment advice.

The 6 inputs and where to find each number

Input What to enter Where to find it Example default
Monthly burn Average net cash out per month, after collections Trailing 3 to 6 months of cash flow statements, adjusted for planned hires $150,000
Runway months Months the raise must fund before the next raise or breakeven Operating plan. Use 18 to 24 for growth companies 18
Uses of funds One-time spend: build-out, equipment, acquisition deposits, EHR or software build Capex budget, vendor quotes, LOI deposits $1,000,000
Buffer % Contingency on burn and uses only. Transaction costs are grossed up separately in the next step Board judgment. 15% to 25% is common 20%
Transaction costs % Legal, accounting, placement, filing and diligence costs as a share of gross raise Engagement letters and counsel estimates 4%
Pre-money valuation Equity value before new money: enterprise value less net debt and other debt-like items Term sheet, or EBITDA times a market multiple from the tables below, then adjusted $12,000,000

Owners get burn wrong more often than any other input. Use cash burn, not accounting loss. A home health or behavioral company that waits 60 to 90 days for payer collections burns more cash than its P&L shows.

The pre-money input is equity value, not enterprise value. Investors start from enterprise value and subtract net debt. In healthcare they also subtract debt-like items: accrued deferred compensation, known payer recoupments or overpayment liabilities, unpaid tax and any shortfall against a normal working-capital level. Each dollar of those items comes straight off the pre-money.

The 4% cost default is our modeling assumption, not a market statistic. Cost loads depend on deal complexity, on whether a placement agent is paid and on how much diligence the investor runs. Enter the figure from your own engagement letters. In the example, moving from 4% to 5% raises the gross raise from $4,625,000 to $4,673,684, an increase of 1.05% (our arithmetic: 0.96 ÷ 0.95 = 1.0105). Each further point adds slightly more, because the divisor shrinks.

The 6 outputs, defined exactly

Output Exact definition
Base need Monthly burn × runway months + uses of funds
Need with buffer Base need × (1 + buffer %)
Gross raise Need with buffer ÷ (1 − transaction costs %)
Transaction costs Gross raise × transaction costs %
Post-money valuation Pre-money valuation + gross raise
Dilution Gross raise ÷ post-money valuation, shown as a percentage

In plain words: take burn times months, add one-time spend and add the buffer. Divide by what is left after costs, because costs come out of the money investors send. New investors own the gross raise as a share of post-money.

Which sizing method fits your business

The calculator handles both methods. What changes is which inputs carry the weight.

Business profile Sizing method Runway input Uses input Typical buffer
Pre-revenue or early healthtech Runway-led 18 to 24 months Product build, compliance work 20% to 25%
Growth-stage services company, burning cash Runway plus uses 12 to 18 months De novo sites, hires, systems 15% to 25%
Cash-positive practice or ASC funding a project Uses-led 0 to 6 months of ramp losses Build-out, equipment, acquisition price 10% to 20%
Platform buying add-ons Uses-led, per deal Integration losses only Purchase price less acquisition debt 15% to 20%

Buffer ranges are our planning guidance, not market statistics. Set the buffer higher when collections are slow, when payer enrollment gates revenue at a new site, or when the plan depends on one hire.

Worked example: $150,000 burn, 18 months, $12 million pre-money

This is a hypothetical multi-site specialty group building two de novo locations. Assumptions: 20% buffer, 4% costs, no debt or debt-like items, no existing option pool, no convertible notes.

Step Calculation Result
Burn for runway $150,000 × 18 $2,700,000
Base need $2,700,000 + $1,000,000 uses $3,700,000
Need with buffer $3,700,000 × 1.20 $4,440,000
Gross raise $4,440,000 ÷ 0.96 $4,625,000
Transaction costs $4,625,000 × 4% $185,000
Post-money $12,000,000 + $4,625,000 $16,625,000
Dilution $4,625,000 ÷ $16,625,000 27.82%

The existing owners keep 72.18%. Costs come to $185,000, not the $177,600 you get from 4% of $4,440,000. Costs apply to every dollar raised, including the dollars raised to pay the costs.

If burn is not flat. The calculator takes one average burn figure. New sites burn more cash while credentialing and payer enrollment clear, so build a monthly cash model first and enter its average. Suppose the real curve is $200,000 a month for the first 6 months and $150,000 after that. Base need rises by $300,000 ($50,000 × 6). After the 20% buffer and the 4% gross-up, the raise grows by $375,000 (our arithmetic: $300,000 × 1.20 ÷ 0.96).

Debt or equity for each use of funds

Equity is the most expensive money a profitable healthcare business can raise. Before entering a uses figure, separate the items a lender will fund.

Use of funds Usually financed with Why
Medical equipment Equipment loan or lease The asset secures the loan
Build-out of a leased site Tenant improvement allowance, then term debt Landlords and banks fund it against the lease and cash flow
Acquisition of a profitable practice Senior debt sized on the target's EBITDA, plus equity for the rest Lenders fund against acquired cash flow
Ramp losses at a new site Equity or a working capital line No collateral until collections start
Software or product build Equity Lenders rarely fund intangible build
Working capital for payer lag Revolving line against receivables Receivables secure the line

Every dollar moved from equity to debt shrinks the gross raise. In the example, financing $600,000 of the $1,000,000 build-out with an equipment loan cuts the gross raise by $750,000 ($600,000 × 1.20 ÷ 0.96), to $3,875,000. Dilution falls from 27.82% to 24.41% ($3,875,000 ÷ $15,875,000, our arithmetic). The debt capacity calculator tests how much the cash flow supports.

How sensitive dilution is to raise size and to pre-money

Dilution equals R ÷ (P + R), where R is the gross raise and P is the pre-money. The two inputs behave differently depending on whether you measure the change in dollars or in percent. Our arithmetic, holding everything else at the base case:

Change from base case Raise Pre-money Dilution Change
Base case $4,625,000 $12,000,000 27.82% n/a
Raise up $1,000,000 $5,625,000 $12,000,000 31.91% +4.10 points
Pre-money down $1,000,000 $4,625,000 $11,000,000 29.60% +1.78 points
Raise up 10% $5,087,500 $12,000,000 29.77% +1.95 points
Pre-money down 10% $4,625,000 $10,800,000 29.98% +2.16 points

In dollars, the raise has more effect. For small changes, a dollar added to the raise moves dilution P ÷ R times as much as a dollar taken off the pre-money. In this example that ratio is about 2.6 ($12,000,000 ÷ $4,625,000). The ratio depends on the deal. A company raising a larger amount against a smaller pre-money sees a lower ratio.

In percent, the two inputs carry equal weight. For small changes, a 1% increase in the raise and a 1% cut in the pre-money move dilution by the same proportion. The 10% rows differ slightly only because the changes are not small.

What this means for owners:

The three tables below come from different datasets with different populations. Read each one on its own terms and do not average across them.

Indicative private-market ranges, 2026. Source: Sikich, Q3 2026 US healthcare M&A update. These are Sikich's indicative EV/EBITDA bands, not medians of a defined sample.

Segment Indicative EV/EBITDA
Physician practice, under $1M EBITDA 5x to 7x
Physician practice, $1M to $3M EBITDA 7x to 9x
Physician practice, $3M to $5M EBITDA 9x to 11x
Physician practice, above $5M EBITDA 11x to 13x
Dental: practices / add-ons / DSO platforms 5x to 9x / 5x to 8x / 9x to 11x
ASC: single-specialty / multispecialty / regional operators 5x to 8x / 6x to 10x / 11x to 17x
Urgent care, under $10M revenue / $10M to $50M revenue 3x to 7x / 6x to 11x
Home health and hospice, small agencies Mid-single digits

Sikich also reports that platforms command a four- to eight-turn premium over add-on practices by specialty, and that the median ASC multiple reached 7.9x in 2025, which it calls the highest in at least eight years.

Closed-transaction medians. Each row names its population. The figures are as reported by each provider.

Population Median multiple Source
U.S. healthcare services control deals, Jan 2023 to Oct 2026, 68 deals with positive EBITDA 9.6x EV/EBITDA (10.1x excluding distressed sales) BuckheadFMV
Same dataset, deals above $200M 11.2x EV/EBITDA and 1.34x EV/revenue BuckheadFMV
Same dataset, ambulatory surgery centers 12.4x EV/EBITDA and 1.24x EV/revenue BuckheadFMV
Same dataset, deals below $10M 2.8x EV/EBITDA and 0.27x EV/revenue. Many are practices bought near asset value. Not a benchmark for a practice with goodwill BuckheadFMV
Closed healthcare small-business sales, under $500K SDE (n=182) 3.4x SDE (middle half 2.7x to 4.2x) Axia Growth, data as of Oct 28, 2026
Same dataset, $500K to $1M SDE (n=42) 3.4x SDE (middle half 2.5x to 4.4x) Axia Growth
Same dataset, $2M to $3M EBITDA (n=13) 5.1x EBITDA (middle half 3.1x to 10.9x) Axia Growth
Same dataset, $5M to $10M EBITDA (n=14) 8.8x EBITDA (middle half 3.4x to 10.7x) Axia Growth
Same dataset, $10M+ EBITDA (n=17) 12.9x EBITDA (middle half 9.4x to 18.5x) Axia Growth

How each dataset was built, as described by each provider:

Reconciling the ASC figures. BuckheadFMV's 12.4x ASC median and Sikich's 5x to 8x single-specialty band describe different deals. BuckheadFMV's ASC median draws on control deals with disclosed EBITDA, which skew larger. That places it inside Sikich's 11x to 17x band for regional operators. A single-specialty center raising equity should anchor to Sikich's 5x to 8x band and the 7.9x 2025 median.

Public-company multiples, U.S., January 2026. Source: Damodaran, NYU Stern, EV/EBITDA and EV/Sales datasets.

Sector Firms EV/EBITDA EV/Sales
Healthcare information and technology 115 21.27x 5.31x
Healthcare products 204 19.78x 4.76x
Drugs (pharmaceutical) 228 15.25x 6.24x
Healthcare support services 104 11.17x 0.46x
Hospitals and healthcare facilities 31 8.86x 1.69x
Total market excluding financials 4,822 16.95x n/a

The two columns come from separate Damodaran files that aggregate differently, so dividing EV/Sales by EV/EBITDA does not give a reliable sector EBITDA margin. Public multiples reflect liquid, scaled companies. They are an upper reference for private healthtech, not a target.

Worked check on the example. At 8x, the midpoint of Sikich's $1 million to $3 million practice band, a $12 million pre-money implies $1.5 million of EBITDA. That holds only if enterprise value equals equity value, which means no debt, no debt-like items and no excess cash. Adjustments move the figure (our arithmetic, same $4,625,000 raise):

Scenario Pre-money (equity value) Post-money Dilution
$1.5M EBITDA × 8x, no debt or cash $12,000,000 $16,625,000 27.82%
$1.5M EBITDA × 8x, $2M net debt and debt-like items $10,000,000 $14,625,000 31.62%
$900K EBITDA × 8x, no debt or cash $7,200,000 $11,825,000 39.11%

The $900K row applies 8x for comparison only. Sikich's band for practices under $1 million of EBITDA is 5x to 7x, so the real pre-money would likely come in lower.

Market-level pricing has also come down. PitchBook data reported in Sikich's Q3 2026 update puts the median healthcare M&A multiple at 14.5x EV/EBITDA in 2024, 13x in 2025 and 11.6x for 2026 year to date through the third quarter. The same data puts the median PE-backed healthcare services buyout at 13.6x EBITDA in 2025, against 13.5x in 2024, with implied target EBITDA of roughly $33 million. Those medians cover larger deals across all of healthcare. They are not practice-level figures. The direction still matters: a pre-money anchored to 2024 comps overstates 2026 pricing. The healthcare valuation multiples guide breaks this out by segment.

Staging the raise: two rounds versus one

Price is the other lever on dilution, and price rises when the company hits milestones. The tables below compare one round against two rounds that deliver the same $4,440,000 of buffered net cash.

Assumptions (our arithmetic):

Hypothetical Gross raise Pre-money Round dilution Owners retain
One round today $4,625,000 $12,000,000 27.82% 72.18%
Round 1 today $2,000,000 $12,000,000 14.29% 85.71%
Round 2 after milestone $2,703,125 $20,000,000 11.91% 88.09%
Two rounds combined $4,703,125 n/a 24.49% 75.51% (85.71% × 88.09%)

Staging saves 3.33 points only if the step-up arrives. Run the Round 2 price as a scenario before committing:

Round 2 pre-money Round 2 dilution Owners retain after both rounds vs. one round
$12,000,000 (down) 18.38% 69.96% 2.22 points worse
$14,000,000 (equal to Round 1 post) 16.18% 71.84% 0.34 points worse
About $14,420,000 15.79% 72.18% Breakeven
$16,000,000 14.45% 73.33% 1.15 points better
$20,000,000 11.91% 75.51% 3.33 points better

The breakeven rule follows from the table. Without repeated fixed costs, staging breaks even when Round 2 prices exactly at Round 1's post-money, here $14 million. The $75,000 second-process cost pushes breakeven to about $14.42 million. Staging has to clear Round 1's post-money by enough to pay for the second process.

The cash clock is the real risk. Round 1 nets $1,920,000. If it funds one de novo site at $500,000, $1,420,000 remains. At $150,000 a month that lasts about 9.5 months. Round 2 has to close inside that window, after the milestone is visible, so the process starts around month 4 or 5. A milestone that slips by one quarter leaves the company raising from a weak position.

Build process time into the inputs. Set Round 1's runway to the months to milestone plus the months a raise takes, then rerun. Take a 6-month milestone plus a 6-month raise, which means 12 months of runway. Round 1 then needs $150,000 × 12 + $500,000 = $2,300,000, or $2,875,000 after a 20% buffer and 4% gross-up. That is $875,000 more than the $2 million in the table, at 19.33% dilution instead of 14.29% ($2,875,000 ÷ $14,875,000, our arithmetic).

The milestone has to be one an investor will pay for:

Milestone Why investors pay for it Evidence to show at Round 2
Second site at cash breakeven Proves the de novo model repeats Monthly site P&L, payer mix, collections lag
Signed payer contract Locks in rate and volume Executed contract, rate schedule, enrollment status
Closed add-on acquisition Adds EBITDA that moves the multiple band Closing financials, quality of earnings
Recurring revenue threshold (healthtech) Lowers risk on the revenue model Cohort retention, contracted backlog

Size the first close to what the current investor pipeline can fund in 90 to 120 days. A $10 million target that the company's traction cannot support stays open for months, and investors read that as other investors passing. Size the target to the investors who have already asked for diligence materials, and have those materials ready using the healthcare data room checklist.

Where healthcare capital went in 2025

Deal type, PE-backed healthcare, 2025 Count Share (our arithmetic)
Add-on acquisitions 664 64.5%
Growth investments 214 20.8%
Leveraged buyouts 151 14.7%
Total 1,029 100%

Source: Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review, drawn from PitchBook and LevinPro HC. The deals involved 420 platform companies and 708 investment firms. PESP says its final count is likely an underestimate.

Growth investments were about one deal in five by count. The busiest subsectors in the PESP data were health IT (151 deals), dental (149), outpatient care (148), medtech (117) and behavioral health (56). The mix matters for sizing:

Reading the dilution number without freezing

Some owners see 27.82% and walk away. The right test is value after the raise, not the ownership percentage. Two hypotheticals on the worked example (our arithmetic):

Outcome after the raise Company equity value Owners' 72.18% is worth vs. $12M today
Raise funds growth $25,000,000 About $18,045,000 +$6,045,000
Raise funds survival, value flat at post-money $16,625,000 About $12,000,000 No gain

In the second case the dilution bought nothing. The raise has to fund something that grows equity value faster than it dilutes the owners.

3 ways the result goes wrong in real deals

  1. The pre-money ignores debt and debt-like items. Investors price enterprise value and subtract net debt, deferred compensation, payer recoupment exposure and any working-capital shortfall. In the example, $2 million of those items moves dilution from 27.82% to 31.62%.
  2. Burn leaves out ramp and reimbursement lag. A flat average understates the early months of a new site. The ramp case above adds $375,000 to the raise.
  3. Term sheet terms raise effective dilution. The option pool basis decides who pays for the pool. Assume no existing pool and a new pool equal to 10% of post-money (our arithmetic):
Pool convention Investors Option pool Existing owners
No pool 27.82% 0% 72.18%
10% of post-money, carved from the pre-money 27.82% 10.00% 62.18%
10% created after the round, all holders diluted pro rata 25.04% 10.00% 64.96%

Under the pre-money convention, the investors' 27.82% stays fixed and the full pool comes out of the owners' share. Notes and SAFEs that convert at a discount add more dilution. Liquidation preferences do not change ownership, but they shift exit proceeds to the new money. Run each clause through the LOI and term sheet red flags checklist.

The sizing pack to finish before the first investor meeting

Investors test the raise amount before they test the pitch. A number backed by these eight documents holds up in diligence. A number typed straight into the calculator does not. Each row shows the figure from the worked example that the document has to support.

Document What it proves Figure it supports in the example
Monthly cash model, 18 months, with a ramp case Burn is cash, not accounting loss, and the ramp is priced $150,000 average burn, ramp case adds $375,000 to the raise
Uses of funds schedule, split into debt and equity Only the uses lenders will not fund are in the equity raise $1,000,000 uses, moving $600,000 to an equipment loan cuts the raise to $3,875,000
Enterprise value to equity value bridge The pre-money already nets out debt and debt-like items $1.5M EBITDA × 8x = $12,000,000, $2M of debt-like items takes it to $10,000,000
Comparable multiple memo The multiple matches the right segment and size band 8x, the midpoint of Sikich's $1M to $3M practice band
Cost estimate from engagement letters The gross-up uses real quotes, not a default 4% = $185,000, 5% raises the gross raise to $4,673,684
Pro forma cap table under each pool convention Owners know their retained stake before the term sheet arrives 72.18% with no pool, 62.18% or 64.96% with a 10% pool
One-round versus staged comparison The board has seen the breakeven price for Round 2 Breakeven at about $14.42 million Round 2 pre-money
Cash-out date and milestone evidence list Round 2 can close before cash runs out Round 1 cash lasts about 9.5 months after one de novo site

Two checks before the pack goes out:

Who invests, who is paid to find investors and how a clinical business is owned can each change the structure behind these numbers. Take those questions to your own attorney, starting from our guides on securities rules for raising capital, physician investors who refer and who can be paid to introduce investors.

What to do after you run the numbers

Questions owners ask

How many months of runway should a healthcare company raise for?

Most growth-stage raises target 18 to 24 months. That covers the build plus the time a company needs to run its next raise or reach cash flow breakeven. Practices and service businesses with positive cash flow need less runway. They should size the raise around specific uses such as a de novo site, an acquisition or equipment. Pre-revenue healthtech needs the longer end because reimbursement and sales cycles run slow.

Should transaction costs be calculated on the net or the gross raise?

On the gross raise. Legal, accounting, placement and filing costs come out of the dollars investors wire, so the company needs to raise more than its net need. The calculator grosses up by dividing the buffered need by one minus the cost percentage. A 4% cost load on a $4,440,000 need produces a $4,625,000 gross raise. Adding 4% on top instead gives $4,617,600. That nets $4,432,896 after costs and leaves the company $7,104 short. The gap widens at higher cost rates.

Is the dilution percentage what founders actually give up?

It is the headline dilution from new money alone. Effective dilution runs higher when investors require an option pool carved from the pre-money or when convertible notes or SAFEs convert at a discount. Liquidation preferences leave ownership unchanged but push value to the new shares on a modest exit. Model each of those against the term sheet before treating the calculator's figure as final.

Is it better to raise less now and more later?

Only if the company hits a milestone that lifts the next round's pre-money far enough above the current round's post-money to pay for the second process. In the worked example, Round 1 is $2,000,000 at $12 million pre-money. Round 2 must net $2,520,000 and carries 4% costs plus an assumed $75,000 of repeated fixed costs, so it raises $2,703,125. On those assumptions, staging beats a single round only if Round 2 prices above about $14.42 million pre-money. At $20 million the owners keep 75.51% instead of 72.18%. At $12 million they keep 69.96%.

Sources